View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Comment
June 6, 2019updated 11 Jul 2022 9:54am

AbbVie shoots for AAN 2020 target readout for Phase II MS trials at current enrolment rate

Source says AbbVie will present data about its Phase II trials of ABT-555 at AAN 2020. AbbVie's official press office declined to comment on the story.

By GlobalData

AbbVie’s Phase II trials of ABT-555 (elezanumab) in various forms of multiple sclerosis (MS) has a target readout at next year’s American Academy of Neurology (AAN) annual meeting, held from 25 April to 1 May 2020, a source said on the sidelines of the recent AAN 2019 in Philadelphia, Pennsylvania.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

MS drug development

ABT-555 is currently in a 165-patient Phase II trial (NCT03737851) for relapsing forms of MS, including relapsing-remitting MS (RRMS) and secondary progressive MS (SPMS), and a 90-patient Phase II trial (NCT03737812) in progressive forms of MS, including SPMS and primary progressive MS (PPMS), according to ClinicalTrials.gov.

Both trials began recruiting a couple of months ago and given the current enrolment rate and its one-year study period, AAN 2020 is a feasible target, unlike the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) 2020 meeting in February 2020, the source said.

The source noted that ACTRIMS is also a major conference that companies target for data presentations. Analysts have noted that an early study had shown promising trends in pharmacokinetics, and one analyst projected peak sales of $3 billion with a launch in 2025. Both experts said that ABT-555 represents a promising development in remyelination in MS, though nascent.

A trial investigator concurred that the first patients were enrolled in both trials a couple of months ago, though he was not sure when data could be expected. He added that recruitment is going well. According to ClinicalTrials.gov, the relapsing MS trial initiated on 11 December 2018 and has a primary completion date of 3 December 2020, while the progressive MS trial initiated on 22 January 2019 and has a primary completion date of 17 September 2020.

A representative from AbbVie at AAN confirmed that the first patients for both trials were enrolled a couple of months ago, while AbbVie’s official press office declined to comment on the story.

by Shuan Sim in New York Shuan Sim is a Reporter for Pharmaceutical Technology parent company GlobalData’s investigative journalism team. A version of this article originally appeared on the Insights module of GlobalData’s Pharmaceutical Intelligence Center. To access more articles like this, visit GlobalData.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology